# Longitudinal Surveillance of COVID-19 Antibodies in Pediatric Healthcare Workers

**Authors:** Dunia Hatabah, Sneh Lata Gupta, Grace Mantus, Patrick Sullivan, Stacy Heilman, Andres Camacho-Gonzalez, Deborah Leake, Mimi Le, Mark Griffiths, Carson Norwood, Samuel Shih, Rawan Korman, Giorgi Maziashvili, Chris A. Rees, Laura Benedit, Bridget A. Wynn, Mehul Suthar, Miriam B. Vos, Jens Wrammert, Claudia R. Morris

PMC · DOI: 10.3390/vaccines13020163 · Vaccines · 2025-02-07

## TL;DR

This study tracks antibody levels in pediatric healthcare workers over time to understand how vaccination and infection affect immunity against COVID-19 and related coronaviruses.

## Contribution

The study provides longitudinal data on antibody durability and cross-reactivity in vaccinated and infected pediatric healthcare workers.

## Key findings

- Vaccinated individuals had higher anti-spike IgG titers than non-vaccinated and naïve individuals.
- A single vaccine dose was sufficient to maximize titers in previously infected participants.
- Anti-spike titers declined after 9 months post-vaccine but remained stable after a booster.

## Abstract

Background: Vaccines against COVID-19 target the spike protein. There is minimal information on longitudinal COVID-19 immune profiling in recovered versus naïve and vaccinated versus non-vaccinated healthcare workers (HCWs). Methods: This is a prospective longitudinal observational cohort of pediatric HCWs (pHCWs) conducted during 2020–2022 at an academic center, exploring the impact of COVID-19 vaccination on immunoglobulin G (IgG) antibody titers over time and cross-reactivity with other coronaviruses, including SARS-CoV-1, MERS-CoV, and seasonal coronaviruses (HCoV-HKU1 and HCoV-OC43). Results: A total of 642 pHCWs initially enrolled, and 337 participants had repeat IgG titers measured post-vaccine and post-booster. Most participants were female, median age range of 31–40 years. Anti-spike was higher in all vaccinated individuals versus non-vaccinated (p < 0.0001) and naïve versus infected (p < 0.0001). A single dose of vaccine was sufficient to attain maximum titers in recovered participants versus naïve who received both doses of vaccine. Anti-spike titers dropped significantly at 9 months after the primary series, whereas sustained anti-spike titers were observed at 9 months post-booster. Conclusions: All vaccinated pHCWs developed antibodies to spike. COVID-19 infection and/or vaccination yielded antibodies that cross-reacted to SARS-CoV-1, MERS-CoV, HCoV-HKU1, and HCoV-OC43. Anti-spike titers were more durable post-booster compared to the primary series. Longitudinal immune profiling of COVID-19 responses provides vital data to shape public health policies, optimize vaccine strategies, and strengthen pandemic preparedness.

## Linked entities

- **Proteins:** CHMP5 (charged multivesicular body protein 5)
- **Diseases:** COVID-19 (MONDO:0100096)

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382)
- **Species:** Middle East respiratory syndrome-related coronavirus (no rank) [taxon 1335626], Human coronavirus HKU1 (no rank) [taxon 290028], Human coronavirus OC43 (no rank) [taxon 31631]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC11861628/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11861628/full.md

## References

48 references — full list in the complete paper: https://tomesphere.com/paper/PMC11861628/full.md

---
Source: https://tomesphere.com/paper/PMC11861628